The next generation of biomarkers and companion diagnostics will require the development of technologies capable of conjugating the advances in high throughput techniques in biology with computational methods. Systems biology is poised to contribute through an integrated view, capturing the complexity of the system both in terms of a collection of interacting molecular components, and also in terms of multiple intersecting views. Following this system-centered view, novel approaches have been developed for the identification of signatures of both disease processes and drug mode of action with the promising perspectives of better diagnosis of disease and of the discovery of more efficacious and safe drugs.
Schematic representation of the integrative approach of systems biology which allows the translation from molecular phenomena to biomarker discovery and companion diagnostics with potential applications in clinical settings and in drug discovery
A novel signature used to predict responders (green) from non-responders (red) to a pharmaceutical treatment (Desatinib) from PBMC transcriptional profiles (Dataset: GEO accession number GSE33224). Each node represents an expression profile of PBMC cells of a patient, and the edges connecting them have length proportional to the inverse of their degree of similarity; the absence of an edge between two nodes indicates a negligible degree of similarity. The figure includes profiles taken right before (light color) and 12 months after onset of the therapy (dark color).
Caberlotto L. and Lauria M. Systems biology meets OMIC technologies: novel approaches to biomarker discovery and companion diagnostic development. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Molecular Diagnostics on Feb 15 2015, available online: http://www.tandfonline.com/doi/abs/10.1586/14737159.2015.975214